Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma

Show other versions (1)

Abstract The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL‐302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL‐302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a st...

Full description

Bibliographic Details
Main Authors: Sofie Mohlin, Karin Hansson, Katarzyna Radke, Sonia Martinez, Carmen Blanco‐Apiricio, Cristian Garcia‐Ruiz, Charlotte Welinder, Javanshir Esfandyari, Michael O'Neill, Joaquin Pastor, Kristoffer vonStedingk, Daniel Bexell
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:EMBO Molecular Medicine
Subjects:
cisplatin
IBL‐302
multikinase inhibition
neuroblastoma
PI3K
Online Access:https://doi.org/10.15252/emmm.201810058

Internet

https://doi.org/10.15252/emmm.201810058

Similar Items